RecruitingNCT06819410
Efficacy and Safety of Amphotericin B and Azoles in the Treatment of Invasive Fungal Disease
A Retrospective Clinical Study on the Efficacy and Safety of Amphotericin B Compared With Azoles in the Treatment of Invasive Fungal Disease
Sponsor
Sichuan Provincial People's Hospital
Enrollment
1,000 participants
Start Date
May 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Efficacy and safety of amphotericin B and azoles in the treatment of invasive fungal disease
Eligibility
Inclusion Criteria2
- There is no age limit, gender is not limited
- Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days.
Exclusion Criteria2
- Patients with incomplete data or other factors affecting the clinical outcome judgement
- Patients who are judged by the investigator to be unsuitable to participate in this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06819410
Related Trials
Immunomonitoring of Mold Invasive Infections
NCT062851881 location
Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases
NCT071357781 location
FungiScope - A Global Emerging Fungal Infection Registry
NCT017313531 location
Fungus-specific immune cells for bone marrow transplant patients with invasive fungal disease
ACTRN126180015402024 locations